Login to Your Account


Sneeze breeze? No FDA ragweed quibbles for Merck, Alk-Abello

By Randy Osborne
Staff Writer

Friday, January 24, 2014
Briefing papers for the meeting next week of the FDA’s Allergenic Products Advisory Committee suggest that the panel will green-light the sublingual ragweed allergy therapy from Alk-Abello A/S and Merck and Co. Inc., just as the grass-pollen allergy tablet sailed through last month.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription